Budget and staffing cuts at the FDA under President Trump threaten the timely development and approval of new drugs, according to pharmaceutical companies' SEC filings. There are concerns that executive actions could delay FDA oversight and regulatory activities, leading to a freeze on drug approvals. Companies like Xenon Pharmaceuticals and Rezolute express worry that these disruptions will negatively impact their research and development efforts, as the FDA's regular inspections and reviews are crucial for bringing new treatments to market.
The Trump Administration has enacted several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine regulatory and oversight activities.
DOGE's mandate to "reduce expenditures" at agencies like the FDA would slow down their work, significantly impacting our drug development activities.
Collection
[
|
...
]